grant
Overcoming Therapy Resistance in SCLC
Organization UT SOUTHWESTERN MEDICAL CENTERLocation DALLAS, UNITED STATESPosted 1 Mar 2024Deadline 28 Feb 2029
NIHUS FederalResearch GrantFY20252'-deoxy-guanosineActivated Natural Killer CellApoptosisApoptosis PathwayBody TissuesBypassCALL proteinCDDPCamL1 Gene ProductCancersCell AgingCell BodyCell Communication and SignalingCell CountCell Cycle ArrestCell Cycle CheckpointCell LineCell NumberCell SenescenceCell SignalingCell Surface Glycoprotein L1Cell SurvivalCell ViabilityCell divisionCellLineCellsCellular AgingCellular SenescenceChemoresistanceChemotherapy and RadiationChemotherapy and/or radiationChestChromosomesCis-diammine-dichloroplatinumCis-diamminedichloridoplatinumCis-diamminedichloro Platinum (II)Cis-dichloroammine Platinum (II)Cis-platinous Diamine DichlorideCis-platinum IICis-platinum II Diamine DichlorideCisplatinCisplatinaCisplatinumClinical Trials DesignCysplatynaCytotoxic cellDNADNA DamageDNA Damage RepairDNA InjuryDNA RepairDNA ReplicationDNA SynthesisDNA biosynthesisDataDeoxyguanosineDeoxyribonucleic AcidDependenceDevelopmentDichlorodiammineplatinumDiseaseDisorderDissociationDoseEPEGEnzyme GeneEnzymesEposideEtoposideExtensive StageExtraordinary responderF11 GlycoproteinGeneralized GrowthGoalsGrowthGuanineHoloenzymesHumanHuman Cell LineIFNImmuneImmune EvasionImmune mediated therapyImmune responseImmune systemImmunesImmunochemical ImmunologicImmunocompetentImmunocompromisedImmunocompromised HostImmunocompromised PatientImmunologicImmunologicalImmunologicallyImmunologically Directed TherapyImmunologicsImmunosuppressed HostImmunotherapyIn VitroIncidenceIndividualInfiltrationInnate ImmunityInterferon Type IInterferonsIntracellular Communication and SignalingK lymphocyteL1 Cell Adhesion MoleculeL1CAMLastetLigandsLimited StageLymphocytic InfiltrateM PhaseMalignant CellMalignant NeoplasmsMalignant TumorMediatingMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMiceMice MammalsMitosisMitosis StageMitoticModelingModern ManMouse Cell LineMurineMusNGF-Inducible GlycoproteinNILE GlycoproteinNILE ProteinNK CellsNSCLCNSCLC - Non-Small Cell Lung CancerNative ImmunityNatural ImmunityNatural Killer CellsNeoplasm MetastasisNerve Growth Factor-Inducible Large External GlycoproteinNeural Adhesion Molecule L1Neural Cell Adhesion Molecule L1Non-MalignantNon-Small Cell Lung CancerNon-Small-Cell Lung CarcinomaNon-Specific ImmunityNonspecific ImmunityNormal CellOat cell carcinomaOncogene ActivationPARP InhibitorPARP-1 inhibitorPARPiPD-L1 antibodyPDX modelPathway interactionsPatient derived xenograftPatientsPeyrone's ChloridePeyrone's SaltPlatinum DiamminodichloridePoly(ADP-ribose) Polymerase InhibitorPoly(ADP-ribose) polymerase 1 inhibitorPrimary NeoplasmPrimary TumorProductionPrognosisProgrammed Cell DeathProteinsRadiationRadiation therapyRadiotherapeuticsRadiotherapyRecommendationRegimenRelapseReplicative SenescenceResearch PriorityResistanceSecondary NeoplasmSecondary TumorSignal TransductionSignal Transduction SystemsSignalingSmall Cell Lung CancerSolid NeoplasmSolid TumorStrains Cell LinesT cell responseT-CellsT-LymphocyteTelomeraseTelomere ShorteningTemodalTemodarTestingTherapeuticThoraceThoracicThoraxTissue GrowthTissuesToxic effectToxicitiesTreatment EfficacyTumor CellTumor ImmunityUnscheduled DNA SynthesisVepesidWorkaPD-L1aPD-L1 antibodiesadaptive immunityanaloganti programmed cell death ligand 1anti programmed cell death protein ligand 1anti-PD-(L)1anti-PD-1/PD-L1anti-PD-L1anti-PD-L1 antibodiesanti-PD-L1 monoclonal antibodiesanti-PDL-1anti-PDL1anti-PDL1 antibodiesanti-tumor effectanti-tumor immune responseanti-tumor immunityantiPD-L1antigen-specific T cellsantitumor effectantitumor immunitybiological signal transductioncancer cellcancer immunitycancer initiationcancer metastasiscancer survivalcell cycle check pointcheck point blockadecheckpoint blockadechemo-/radio-therapychemo-radiotherapychemo/radiation therapychemoradiationchemoradiation therapychemoradiation treatmentchemoradiotherapychemoresistantchemotherapychemotherapy and radiotherapychemotherapy resistancechemotherapy resistantcis dichlorodiammineplatinumcis platinum compoundcis-Diaminedichloroplatinumcis-Diamminedichloroplatinumcis-Diamminedichloroplatinum(II)cis-Dichlorodiammineplatinum(II)cis-Platinumcomparable efficacycomparative efficacycompare efficacycultured cell linecytotoxicdetermine efficacydevelopmentaleffective therapyeffective treatmentefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationevaluate efficacyexamine efficacyexceptional respondersextreme respondershost responsehumanized micehumanized mouseimmune check point blockadeimmune checkpoint blockadeimmune competentimmune evasiveimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunogenicityimmunoresponseimmunosuppressed patientimprovedin vitro Modelinhibitorinnovateinnovationinnovativeintervention efficacylung oat cell carcinomalung small cell neuroendocrine carcinomamalignancymethazolastonemicronucleusmouse modelmurine modelneoplasm/cancerneoplastic cellneuroendocrine cancerneuroendocrine malignancynew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnonmalignantnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyoat cell cancerontogenypathwaypatient derived xenograft modelpositive respondersprematureprematuritypreventpreventingpulmonaryradiation or chemotherapyradiation treatmentradio-chemo-therapyradio-chemotherapyradiochemotherapyrational designreplication stressreplicative agingresistantresponseresponse to therapyresponse to treatmentside effectsmall cell lung carcinomasmall cell undifferentiated carcinomasmall moleculestandard of caresynergismtelomeretelomere attritiontemozolomidetherapeutic efficacytherapeutic responsetherapeutically effectivetherapy efficacytherapy responsethymus derived lymphocytetreatment responsetreatment responsivenesstreatment with radiationtumortumor cell metastasisαPD-L1αPD-L1 antibodiesαPDL1
Description preview
PROJECT SUMMARY/ABSTRACT
Small cell lungcancer (SCLC) is a pulmonary neuroendocrine cancer with very poor prognosis and limited
effective therapeutic options. Chemotherapy has been used for the past 30 years as for the treatment for SCLC.
While most SCLCs initially respond to this treatment, nearly all relapse. Recently, immunotherapies have been…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click